Precirix launches CAM-FAP-Ga-68 Academic Access Program

Brussels, Belgium 26 AUG 2024 – Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors, is proud to
launch an academic access program for their proprietary molecule CAM-FAP-Ga-68. The primary aim of the program is to broaden the availability of innovative radiopharmaceuticals that are still under investigation to physicians and researchers. By providing access to CAM-FAP-Ga68, the program supports research, enhances clinical knowledge, and fosters collaborations that may lead to new applications or improvements in patient care.

Go to Precirix.com/FAP-access for more information and to get in contact with a CAM-FAP Academic Access Program team member. CAM-FAP-Ga-68 is a Fibroblast Activation Protein (FAP) imaging tracer used in medical imaging to target and visualize fibroblast activation protein (FAP) overexpressed in a variety of different tumor types. FAP is typically absent or expressed at very low levels in most normal tissues, making it an attractive target for imaging in oncology. “We are delighted to make our CAM-FAP molecule available to physicians in order to expand the options available for FAP imaging and future therapies” said Tom Plitz, CEO of Precirix. Single-domain antibodies are excellent targeting vectors for targeted radiotherapies as they combine the benefits of conventional mono-clonal antibodies and small molecules. They consist of a single monomeric variable antibody domain derived from camelids, which combine the high target affinity & specificity of antibodies with excellent stability and small molecule-like DMPK, ensuring fast clearance, efficient tumor penetration and allowing to achieve exceptionally long tumor retention.

About Precirix
Precirix is a private biopharmaceutical company dedicated to extending and improving the lives of cancer patients through developing precision radiopharmaceuticals using camelid single domain antibodies (sdAb) labelled with radioisotopes. The company’s Fibroblast Activation Protein (FAP)- targeting program is advancing Precirix’ unique radiometal platform into the clinic. Precirix’ HER2- targeting CAM-H2-I-131 asset is Phase 2 ready. Precirix’ technology allows for a theranostic approach, where patients can be selected using an imaging version of the product, followed by a therapeutic dose for treatment.

For further information about Precirix, please contact:
Precirix NV
Tom Plitz, CEO
tom.plitz@precirix.com
info@precirix.com
http://www.precirix.com